Independent
Tenure on this board
9.7 yrs
Also a director at
Instil Bio Inc (TIL)
Meeting calendar
STTK · Annual meeting · Thursday, July 10, 2025
Shattuck Labs Inc
3 nominees · 2 ballot items.
Election of three Class II directors to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified; and ratification of KPMG LLP as the Company’s independent auditor for 2025 (with any other matters that may properly come before the Annual Meeting).
Market cap
$499M
1Y TSR
+400.5%
Board grade
C
Record date
May 14, 2025
Filing
DEF 14A
Meeting concluded · Jul 10, 2025
Follow how the vote landed and what changed on Shattuck Labs Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot2
- 1
Election of three Class II director nominees to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified
ManagementBoard: FORElection of three Class II director nominees named in the Proxy Statement to serve until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified.
- 2
Ratification of Independent Auditor Selection
ManagementBoard: FORRatification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2025.
Director elections
Nominees on the ballot3
Independent
Tenure on this board
8.5 yrs
Also a director at
Acumen Pharmaceuticals Inc (ABOS)
Independent
Tenure on this board
1.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 12.9% | 9,865,558 | $63M |
| 2 | ORBIMED ADVISORS LLCActivist | 8.2% | 6,306,127 | $41M |
| 3 | Redmile Group, LLC | 7.2% | 5,539,724 | $36M |
| 4 | Prosight Management, LP | 6.5% | 5,004,439 | $32M |
| 5 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 6.1% | 4,644,957 | $30M |
| 6 | NEXTBio Capital Management LP | 4.1% | 3,149,907 | $20M |
| 7 | VANGUARD CAPITAL MANAGEMENT LLC | 3.0% | 2,277,176 | $15M |
| 8 | PRICE T ROWE ASSOCIATES INC /MD/ | 2.3% | 1,782,788 | $11M |
| 9 | CLARK ESTATES INC/NY | 1.9% | 1,475,648 | $9M |
| 10 | PINNACLE ASSOCIATES LTD | 1.8% | 1,368,223 | $9M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Shattuck Labs Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Esperion Therapeutics IncESPR
Special meeting·Jul 8, 2026·$814M
Reference
Frequently asked questions
- When is the Shattuck Labs Inc 2025 annual meeting?
- Shattuck Labs Inc (STTK) holds its 2025 annual shareholder meeting on Thursday, July 10, 2025.
- What is the record date for the Shattuck Labs Inc 2025 meeting?
- The record date for the Shattuck Labs Inc 2025 meeting is Wednesday, May 14, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Shattuck Labs Inc's 2025 meeting?
- The board is presenting 3 director nominees at the Shattuck Labs Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Shattuck Labs Inc 2025 meeting?
- Shareholders will vote on 2 proposals at the Shattuck Labs Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.